LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
What is Lifesci Capital’s Forecast for TARA Q1 Earnings?
Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...
Lifesci Capital Predicts Immunome FY2024 Earnings
Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...
Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...